Logo image
Immunostimulatory cancer chemotherapy using local ingenol-3-angelate and synergy with immunotherapies
Journal article   Peer reviewed

Immunostimulatory cancer chemotherapy using local ingenol-3-angelate and synergy with immunotherapies

T T Thuy, J Gardner, D Hoang-Le, C W Schmidt, K P MacDonald, E Lambley, W A Schroder, Steven Ogbourne and A Suhrbier
Vaccine, Vol.27(23), pp.3053-3062
2009
url
https://doi.org/10.1016/j.vaccine.2009.03.025View
Published Version

Abstract

cancer vaccines metastases
Ingenol-3-angelate is a new local chemotherapeutic agent in clinical trails that induces primary necrosis of tumour cells and transient local inflammation. Here we show that cure of subcutaneous tumours with ingenol-3-angelate (PEP005) resulted in the generation of anti-cancer CD8 T cells that could regress metastases. Furthermore, PEP005-mediated cure synergized with several CD8 T cell-based immunotherapies to regress further distant metastases. PEP005 was shown to have adjuvant properties, being able to upregulate CD80 and CD86 expression on dendritic cells in vivo, and to promote CD8 T cell induction when co-delivered with a protein antigen. PEP005 thus emerges as a unique local chemotherapeutic immunostimulatory debulking agent that could be used in conjunction with immunotherapies to promote regression of metastases.

Details

Metrics

2 File views/ downloads
487 Record Views

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
Web Of Science research areas
Immunology
Medicine, Research & Experimental

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Logo image